Interleukin-2 production pathway

The **Interleukin‑2 production pathway** refers to the complex intracellular signaling events that regulate the synthesis and secretion of interleukin‑2 (IL‑2), a cytokine critical for immune system function. This is not a single molecule or receptor, but rather a network of molecular interactions primarily in T cells and dendritic cells. IL‑2 production is tightly controlled by several upstream signals, most notably through engagement of the T cell receptor (TCR) with antigen presented by HLA-peptide complexes, along with costimulatory signals such as CD28. These events activate phospholipase C-dependent pathways leading to increased intracellular calcium and activation of key transcription factors including NFAT, NFκB, and AP‑1[1][3]. Additional regulatory input comes from cytokines like transforming growth factor-beta which can suppress IL‑2 gene expression via SMAD proteins[2]. Downstream of its own receptor binding, IL‑2 triggers three major pathways in target cells: JAK/STAT, PI3K/Akt/mTOR, and MAPK/ERK. These promote survival, proliferation, differentiation of lymphocytes—especially T cells—and modulate immune responses[1][2]. Because this entry describes a **signaling or production pathway** rather than an individual protein target such as a receptor or enzyme subunit, it should not be considered a canonical therapeutic target itself. Instead, components within this pathway—such as the interleukin 2 protein itself ("Interleukin 2"), its high-affinity trimeric receptor ("Interleukin 2 receptor"), Janus kinases JAK1/JAK3 ("Janus kinase 1", "Janus kinase 3"), STAT5 ("Signal transducer and activator of transcription 5")—are more appropriate entries for structured drug-target information[1][3].

Other names

IL-2 signaling pathwayIL-2 activation and signaling pathwayInterleukin 2 gene expression regulationImmune response - IL-2 activation pathway